Y A Kucheryavyy

48PUBLICATIONS
157CO-AUTHORS
Behavioural epidemiologyEpidemiological methodsPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (48)

|Jun 26, 2026
Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg).

|May 04, 2026
Efficacy and Safety of Tegoprazan in <i>Helicobacter pylori</i> Eradication: An Umbrella Review of Meta-Analyses.

|Jan 28, 2026
Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review.

Igor V Maev, Alsu R Khurmatullina, Dmitrii N Andreev

|Oct 28, 2025
Tailored Therapy vs. Empirical Therapy for <i>Helicobacter pylori</i> Eradication: An Umbrella Review of Systematic Reviews and Meta-Analyses.

Dmitrii N Andreev, Alsu R Khurmatullina, Igor V Maev

|Aug 30, 2025
[Study on the efficacy of combination therapy with rifaximin and <i>Saccharomyces boulardii</i> CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors].

I V Maev, D N Andreev, R I Shaburov

|Aug 30, 2025
[Serological markers as predictors of the severity of gastric mucosal atrophy in autoimmune and <i>Helicobacter рylori</i>-associated gastritis].

M V Chebotareva, K A Nikolskaya, D N Andreev

Pageof 8

Frequent Collaborators

36 joint publications

Igor V Maev

16 joint publications

Dmitry S Bordin

15 joint publications

Yury A Kucheryavyy

11 joint publications

Philipp S Sokolov